Needham analyst Chad Messer reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) Inc on Tuesday, setting a price target of $74, which is approximately 139.56% above the present share price of $30.89.
Messer expects G1 Therapeutics Inc to post earnings per share (EPS) of -$0.31 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in G1 Therapeutics, with an average price target of $78.
The analysts price targets range from a high of $82 to a low of $74.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $26.6 million and a net profit of -$9.75 million. The company's market cap is $1.18 billion.
According to TipRanks.com, Needham analyst Chad Messer is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.1% and a 53.85% success rate.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.